Literature DB >> 18638466

Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis.

Naoki Inui1, Noriyuki Enomoto, Takafumi Suda, Yasunori Kageyama, Hiroshi Watanabe, Kingo Chida.   

Abstract

OBJECTIVE: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific markers for rheumatoid arthritis (RA) and useful for predicting RA development and progression. However, it has not been fully determined whether anti-CCP antibodies are associated with pulmonary diseases in RA patients. In the present study, we aimed to elucidate the relationships between anti-CCP antibodies and pulmonary diseases, particularly interstitial lung disease (ILD) and bronchiolitis. DESIGN AND METHODS: Using an enzyme-linked immunosorbent assay, the presence of serum anti-CCP antibodies was examined in 18 RA patients with ILD and bronchiolitis who were diagnosed based on pathologic findings. A further 36 RA subjects without any pulmonary diseases served as a reference population.
RESULTS: No significant differences were found for the prevalences and levels of anti-CCP antibodies between patients with and without ILD and follicular bronchiolitis.
CONCLUSION: Detection of serum anti-CCP antibodies has no association with pulmonary diseases in RA patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638466     DOI: 10.1016/j.clinbiochem.2008.06.014

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  26 in total

1.  Interstitial lung disease in rheumatoid arthritis.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

2.  Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Authors:  Tracy J Doyle; Avignat S Patel; Hiroto Hatabu; Mizuki Nishino; Guodong Wu; Juan C Osorio; Maria F Golzarri; Andres Traslosheros; Sarah G Chu; Michelle L Frits; Christine K Iannaccone; Diane Koontz; Carl Fuhrman; Michael E Weinblatt; Souheil Y El-Chemaly; George R Washko; Gary M Hunninghake; Augustine M K Choi; Paul F Dellaripa; Chester V Oddis; Nancy A Shadick; Dana P Ascherman; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

Review 3.  The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis.

Authors:  Lindsay B Kelmenson; M Kristen Demoruelle; Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

4.  Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease.

Authors:  Aryeh Fischer; Joshua J Solomon; Roland M du Bois; Kevin D Deane; Amy L Olson; Evans R Fernandez-Perez; Tristan J Huie; Allen D Stevens; Mary B Gill; Avi M Rabinovitch; David A Lynch; David A Burns; Isabel S Pineiro; Steve D Groshong; Rosane D Duarte Achcar; Kevin K Brown; Richard J Martin; Jeffrey J Swigris
Journal:  Respir Med       Date:  2012-04-12       Impact factor: 3.415

Review 5.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

6.  STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population.

Authors:  Ma de Jesús Durán-Avelar; Norberto Vibanco-Pérez; Raquel Rocío Hernández-Pacheco; América Del Carmen Castro-Zambrano; Liliana Ortiz-Martínez; José Francisco Zambrano-Zaragoza
Journal:  Clin Rheumatol       Date:  2016-05-28       Impact factor: 2.980

7.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

8.  Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis.

Authors:  Sisi Xie; Shu Li; Bilin Chen; Qing Zhu; Lichang Xu; Fen Li
Journal:  Clin Rheumatol       Date:  2021-06-29       Impact factor: 2.980

Review 9.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

10.  Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.

Authors:  José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante
Journal:  Clin Rheumatol       Date:  2015-08-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.